Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...

Osteosarcoma primarily affects long bones in teenagers and young adults, requiring early diagnosis for effective treatment. Treatment strategies vary by stage, with surgery and chemotherapy as primary ...

Osteosarcoma is the most prevalent primary malignant bone tumor in children and adolescents. The current standard treatment involves a combination of chemotherapy and radical surgical resection. This ...

A new type of immunotherapy has shown promising preclinical results against a bone cancer called osteosarcoma, as part of a study in mice. A new type of immunotherapy, developed by UCL researchers, ...

A major driver of the bone cancer osteosarcoma has been discovered by researchers from UCL, EMBL EBI and the Royal National Orthopaedic Hospital, providing insights that could help to predict cancer ...

Primary types of bone cancer include osteosarcoma, Ewing sarcoma, and chordoma. Secondary bone cancer develops as a result of cancer that has spread from another area of the body. Doctors broadly ...

The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.

CLEVELAND — There's certainly something to be said for being in the right place at the right time. Dr. Alex Huang overheard a conversation between colleagues discussing a new type of drug being tested ...

A research team at Johns Hopkins Medicine has created and trained a machine learning model to calculate percent necrosis (PN) - or, what percentage of a tumor is "dead" and no longer active - in ...